Critical Aspects Concerning the Development of a Pooling Approach for SARS-CoV-2 Diagnosis Using Large-Scale PCR Testing.
COVID-19
RNA extraction
RT-qPCR
SARS-CoV-2
molecular diagnostic
nasopharyngeal swabs
sample pooling
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
13 05 2021
13 05 2021
Historique:
received:
30
03
2021
revised:
04
05
2021
accepted:
05
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
2
7
2021
Statut:
epublish
Résumé
The primary approach to controlling the spread of the pandemic SARS-CoV-2 is to diagnose and isolate the infected people quickly. Our paper aimed to investigate the efficiency and the reliability of a hierarchical pooling approach for large-scale PCR testing for SARS-CoV-2 diagnosis. To identify the best conditions for the pooling approach for SARS-CoV-2 diagnosis by RT-qPCR, we investigated four manual methods for both RNA extraction and PCR assessment targeting one or more of the RdRp, N, S, and ORF1a genes, by using two PCR devices and an automated flux for SARS-CoV-2 detection. We determined the most efficient and accurate diagnostic assay, taking into account multiple parameters. The optimal pool size calculation included the prevalence of SARS-CoV-2, the assay sensitivity of 95%, an assay specificity of 100%, and a range of pool sizes of 5 to 15 samples. Our investigation revealed that the most efficient and accurate procedure for detecting the SARS-CoV-2 has a detection limit of 2.5 copies/PCR reaction. This pooling approach proved to be efficient and accurate in detecting SARS-CoV-2 for all samples with individual quantification cycle (Cq) values lower than 35, accounting for more than 94% of all positive specimens. Our data could serve as a comprehensive practical guide for SARS-CoV-2 diagnostic centers planning to address such a pooling strategy.
Identifiants
pubmed: 34067983
pii: v13050902
doi: 10.3390/v13050902
pmc: PMC8152296
pii:
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : UEFISCDI-FEDER
ID : BIOGENONCO -ID P_40_318; MySMIS Code: 105774
Références
Elife. 2020 Oct 28;9:
pubmed: 33112236
Travel Med Infect Dis. 2020 Sep-Oct;37:101673
pubmed: 32311437
J Med Virol. 2020 Nov;92(11):2306-2307
pubmed: 32369202
JAMA. 2020 May 19;323(19):1967-1969
pubmed: 32250394
Expert Rev Mol Diagn. 2020 May;20(5):453-454
pubmed: 32297805
Vox Sang. 2011 Jan;100(1):92-8
pubmed: 21175659
BMJ. 2020 Apr 2;369:m1375
pubmed: 32241884
J Clin Virol. 2020 Jul;128:104382
pubmed: 32388468
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
Am J Epidemiol. 2020 May 5;189(5):363-364
pubmed: 32378722
Diagnostics (Basel). 2020 Jun 26;10(6):
pubmed: 32604919
Bull World Health Organ. 2020 Sep 1;98(9):590-598
pubmed: 33012859
J Clin Microbiol. 2020 Apr 23;58(5):
pubmed: 32102856
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Lancet Infect Dis. 2020 Nov;20(11):1231-1232
pubmed: 32530425
Diagnostics (Basel). 2021 Jan 01;11(1):
pubmed: 33401392
Diagnostics (Basel). 2020 Jul 11;10(7):
pubmed: 32664511
Evolution. 2020 Oct;74(10):2429-2434
pubmed: 32880957
Am J Clin Pathol. 2020 May 5;153(6):715-718
pubmed: 32304208
J Clin Virol. 2020 Dec;133:104684
pubmed: 33176236
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512